Skip to content

MapLight Therapeutics, Inc. MPLT Operating Lease Liabilities

Operating Lease Liabilities at other companies

Neurocrine Biosciences logo
Neurocrine BiosciencesNBIX
$406.2M-9.2%
Acadia Pharmaceuticals logo
Acadia PharmaceuticalsACAD
$39M-12.6%
LBR
LB Pharmaceuticals Inc Common StockLBRX
$2.74M
MeiraGTx Holdings plc logo
MeiraGTx Holdings plcMGTX
$10.61M+160%
Alto Neuroscience logo
Alto NeuroscienceANRO
$3.56M-19.4%
Xenon Pharmaceuticals logo
Xenon PharmaceuticalsXENE
$5.93M-18.7%

Other financials

Income statement

See full
Operating income-$64.5M-174%
Net income-$60.7M-172%
EPS (diluted)-$1.34+95.4%

Balance sheet

See full
Cash & equivalents$55.7M
Total debt$5.6M
Total equity$399.8M+285%
Total assets$418.8M

Cash flow

See full
Operating cash flow-$51.2M-100%
CapEx$24.0K
Free cash flow-$51.2M

Valuation

See full
Market cap$1.39B
Enterprise value$1.34B

Returns & leverage

See full
Return on equity-216.8%
Debt / equity
Current ratio22.9×

Where this comes from

Reported directly by MapLight Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseLiabilityNoncurrent.

The official record: MapLight Therapeutics, Inc. ’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about MapLight Therapeutics, Inc. 's operating lease liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is MapLight Therapeutics, Inc. 's operating lease liabilities?
MapLight Therapeutics, Inc. (MPLT) reported operating lease liabilities of $4.67M in Q1 2026.
What does operating lease liabilities mean?
Long-term portion of operating lease obligations extending beyond one year, representing committed future rent payments.